Markets
38,040.57
15.12 (0.04%)

Shashikant Singh

# Mutual Fund Unlocked: Ulcer Index, another way of measuring investment risk

A lot of bytes and reams of paper have been used to explain the risk in mutual fund investment and various ways of assessing and evaluating them. The most popular being the standard deviation. Although, it is widely used, there are certain drawbacks of this measure of risk that may not entirely capture the pain of an investor. For example, as an investor, you are not worried much if your investment is continuously moving up. Standard deviation does not differentiate between upside and downside movement and treats both in a similar fashion. Moreover, it fails to capture series of losses that result in substantial fall in the investment value.

Ulcer Index developed by Peter G. Martin correctly captures the investor’s pain, which contains more information compared to standard deviation. Ulcer Index addresses the real concerns of investors and measures both the percentage of downfall and for what time such fall sustained from earlier highs.

Ulcer index is calculated as follows for ‘xx’ period.

Percentage Drawdown = [(Close – ‘xx’ period High Close)/’xx’- period High Close] x 100

Squared Average = (‘xx’-period Sum of Percentage Drawdown Squared)/’xx’

Ulcer Index = Square Root of Squared Average

The following graph and explanation picked from his book correctly explain why standard deviation might not be the right metric to calculate risk and investor’s pain.

• The three hypothetical investments in the chart above have the same annualized return (-0.52%/year) and the same SD (4.66%/month), but no rational investor would consider them as having the same risk.

The longer the period, the better you can judge the performance of the investment. Daily and weekly NAVs will give you a better picture of investor’s stress.

The way to interpret ulcer index is lower the better and hence if a fund has Ulcer index of zero, the investment would have never lost money. This index should be used to evaluate the performance of different funds in terms of protecting the downside risk. Therefore, if you are a risk aversive investor you should check this index for different funds that you are contemplating to invest in.

Print
5.0

## IPO Market

Company Name Listing
Date
Listing
Price
Date
Price
Volume
(Nos)
NDR Auto Components Ltd. 30/07/2020 150.05 07/08/2020 120.35 2,226
Rossari Biotech Ltd. 23/07/2020 670.00 07/08/2020 753.65 744,142
Borosil Ltd. 22/07/2020 208.00 07/08/2020 161.15 89,181
Aarti Surfactants Ltd. 14/07/2020 505.00 07/08/2020 284.00 2,059
ABB Power Products and Systems India Ltd. 30/03/2020 714.00 07/08/2020 881.30 92,145

## SME Market

Company Name Issue Open
Date
Isuue Closing
Date
Issue
Price
BID
FROM
BID
TO
List
Date
List
Price
Last
Price
SM Auto Stamping Ltd. 2020-03-03 2020-03-05 18 0.00 0 2020-03-16 18 16
RO Jewels Ltd. 2020-03-12 2020-03-17 36 0.00 0 2020-03-25 0 36
Cospower Engineering Ltd. 2020-03-17 2020-03-19 51 0.00 0 2020-03-27 0 60
Cospower Engineering Ltd. 2020-03-17 2020-03-19 56 0.00 0 2020-03-27 0 60
DJ Mediaprint & Logistics Ltd. 2020-03-26 2020-03-31 20 0.00 0 2020-04-13 21 35

## Five stocks with selling interest

Ganesh Pawar / Article rating: 3.2

The market opened in red on August 7, 2020, overall volumes in futures & options currently stand at 6,09,80,826 crore contracts with a turnover of Rs. 39,88,372.83 crore.

## Lupin partners with ForDoz Pharma; stock tanks by nearly 6 per cent

Geyatee Deshpande / Article rating: 4.0

Lupin Limited announced that the company’s US-based wholly-owned subsidiary Lupin Pharmaceuticals Inc. has entered into an agreement with ForDoz Pharma Corp (ForDoz).

## Glenmark to launch higher strength version of oral antiviral FabiFlu

Anthony Fernandes / Article rating: 4.7

Global pharma major, Glenmark Pharmaceuticals announced on Thursday that it is launching a 400 mg version of oral antiviral FabiFlu, for the treatment of mild to moderate COVID-19 in India. Glenmark Pharmaceuticals was the first company in the country to have received the regulator’s approval for 400 mg dosage form.

## Q1FY21 results: Lupin net profit drops by 58.88 per cent YoY to Rs 108.7 crore

chinmayee d / Article rating: 5.0

The consolidated net sales reported in Q1FY21 came in at Rs 3,527.86 crore, which declined by 9.02 per cent YoY from Rs 3,877.69 crore in Q1FY20.

## Markets likely to start the day on a cautious note

Karan DSIJ / Article rating: 5.0

As markets witnessed a strong rebound from lower levels and closed above the 11,200 level, the 'buy on dip' strategy worked quite well on Thursday's session.  On Friday, cues from Asian peers are mostly negative and hence, today's session is likely to begin on a cautious note.